3/3/2021 8:34:42 AM
BioMarin Completes Enrollment In Phase2 Study Of Vosoritide For Treatment Of Infants, Young Children With Achondroplasia
3/1/2021 8:11:21 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY21 Rev. Estimate To 1.75 M From 1.87 M
3/1/2021 8:10:59 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q4 21 Rev. Estimate To 430.6 M From 477.0 M
3/1/2021 8:10:43 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 21 Rev. Estimate To 437.0 M From 474.3 M
3/1/2021 8:10:25 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q2 21 Rev. Estimate To 444.6 M From 463.3 M
3/1/2021 8:10:11 AM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q1 21 Rev. Estimate To 438.8 M From 450.4 M
3/1/2021 8:09:02 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY21 Estimate To -0.54 From -0.04
3/1/2021 7:43:27 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q4 21 Estimate To -0.18 From 0.10
3/1/2021 7:43:10 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 21 Estimate To -0.17 From 0.05
3/1/2021 7:41:51 AM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q2 21 Estimate To -0.11 From 0.01
3/1/2021 7:41:39 AM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q1 21 Estimate To -0.08 From -0.21
2/25/2021 4:07:51 PM
BioMarin Q4 EPS $0.12 Vs. $0.08 Year Ago
2/18/2021 4:02:00 PM
BioMarin Appoints Maykin Ho To Board Of Directors
1/10/2021 7:48:51 PM
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results In Adults With Severe Hemophilia A
12/21/2020 8:33:17 AM
BioMarin :Children Treated With Vosoritide Show Cumulative Height Gain Of 3.52 Cm At Year 2 Vs. Untreated Children
11/17/2020 8:30:12 AM
BioMarin Pharmaceutical And Deep Genomics Enter Preclinical Collaboration